Antengene, Junshi Biosciences Partner to Combat Immunotherapy Resistance in China
Event summary
- Antengene and Junshi Biosciences have entered a clinical collaboration to evaluate ATG-037 (oral CD73 inhibitor) in combination with JS207 (PD-1/VEGF bispecific antibody) in Mainland China.
- The collaboration aims to identify clinical signals across multiple solid tumor types, building on Phase I data showing ATG-037 reversing checkpoint inhibitor resistance.
- Phase I/Ib data showed a 33.3% ORR and 100% DCR in CPI-resistant melanoma and a 21.4% ORR and 71.4% DCR in CPI-resistant NSCLC.
- JS207 has demonstrated efficacy in NSCLC, HCC, and RCC, and has received FDA IND approval for a Phase II/III trial.
- The collaboration represents a 'triple-axis' approach targeting immune checkpoint signaling, angiogenesis, and adenosine signaling.
The big picture
The collaboration reflects a growing trend in immuno-oncology towards combination therapies to overcome resistance to existing checkpoint inhibitors, a significant clinical challenge. Antengene's focus on oral small molecule inhibitors like ATG-037 offers a potential advantage over antibody-based approaches, but the success of this partnership will be crucial for both companies to expand their presence in the rapidly evolving Chinese oncology market. Junshi Biosciences’ JS207, with its dual PD-1/VEGF targeting, represents a novel approach to solid tumor treatment, and this collaboration provides a valuable opportunity to validate its efficacy.
What we're watching
- Clinical Efficacy
- The success of the collaboration hinges on demonstrating a statistically significant improvement in clinical outcomes compared to existing therapies in the Phase I/II trials in China, particularly given the competitive landscape of existing checkpoint inhibitors.
- Regulatory Pathway
- Approval timelines in China for combination therapies targeting multiple pathways will be critical, as regulatory hurdles could delay commercialization and impact Antengene's revenue projections.
- Market Adoption
- The adoption rate of this combination therapy among oncologists in China will depend on the cost-effectiveness and perceived benefit relative to existing treatment options, potentially requiring significant market education.
Related topics